Feng Wang1, Lixin Jiang2, Jianlin Li3, Xiao Yu4, Mingchuan Li5, Guochang Wu2, Zhenyu Yu5, Kai Zhou2, Haidi Chu2, Huiyuan Zhai2. 1. Department of Breast Disease, The Second Hospital of Shandong University 247 Beiyuan Street, Tianqiao District, Jinan 250033, Shandong, China ; Department of Breast Disease, Beijing Tiantan Hospital, Capital Medical University Beijing 100050, China. 2. Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital 20 Yuhuangding East Road, Yantai 264000, Shandong, China. 3. Image Diagnostic Center, Yantai Yuhuangding Hospital 20 Yuhuangding East Road, Yantai 264000, Shandong, China. 4. Department of Endocrinology, Yantai Yuhuangding Hospital 20 Yuhuangding East Road, Yantai 264000, Shandong, China. 5. Department of Anesthesiology, Yantai Yuhuangding Hospital 20 Yuhuangding East Road, Yantai 264000, Shandong, China.
Abstract
AIM: Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. METHODS: PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. RESULTS: We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). CONCLUSION: Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.
AIM: Our aim was to investigate the relationship between transcription factor 7-like 2 (TCF7L2) polymorphisms and breast cancer susceptibility. METHODS: PubMed, Embase and CNKI databases were used to search the related studies investigating the correlation between TCF7L2 polymorphisms and breast cancer susceptibility. Pooled ORs and 95% CIs, based on five genetic models, were applied to estimate the association betweenTCF7L2 polymorphisms and breast cancer. A fixed-effect model or a random-effect model was applied according to the between-study heterogeneity. RESULTS: We analyzed six single nucleotide polymorphisms (SNPs) in TCF7L2 gene, namely rs12255372, rs7903146, rs7900150, rs3750805, rs1225404 and rs7003146. The increased risk of breast cancer was associated with TCF7L2 polymorphisms (22 vs. 11: OR=1.16, 95% CI=1.02-1.32; 22+12 vs. 11: OR=1.06, 95% CI=1.02-1.10; 22 vs. 11+12: OR=1.15, 95% CI=1.04-1.27; 2 vs. 1: OR=1.07, 95% CI=1.02-1.13; 12 vs. 11: OR=1.05, 95% CI=1.01-1.09). Among the locus, rs7903146 polymorphism was significantly associated with the risk for breast cancer under five genetic models (TT vs. CC: OR=1.29, 95% CI=1.08-1.53; TT+CT vs. CC: OR=1.09, 95% CI=1.01-1.18; TT vs. CC+CT: OR=1.24, 95% CI=1.05-1.48; T vs. C: OR=1.11, 95% CI=1.04-1.19; CT vs. CC: OR=1.08, 95% CI=1.00-1.17). Additionally, rs7900150 also showed effects on the susceptibility of breast cancer (TT vs. AA: OR=1.22, 95% CI=1.07-1.39; TT+AT vs. AA: OR=1.06, 95% CI=1.00-1.14; TT vs. AA+AT: OR=1.21, 95% CI=1.07-1.37; T vs. A: OR=1.09, 95% CI=1.02-1.15; AT vs. AA: OR=1.04, 95% CI=1.01-1.33). Meanwhile, we found that rs3750805 polymorphism could increased the risk for breast cancer (TT+AT vs. AA: OR=1.12, 95% CI=1.01-1.24). CONCLUSION: Our meta-analysis demonstrates that TCF7L2 polymorphisms may increase the risk for breast cancer.
Authors: Robert A Smith; Debbie Saslow; Kimberly Andrews Sawyer; Wylie Burke; Mary E Costanza; W Phil Evans; Roger S Foster; Edward Hendrick; Harmon J Eyre; Steven Sener Journal: CA Cancer J Clin Date: 2003 May-Jun Impact factor: 508.702
Authors: Mohammad Saud Alanazi; Narasimha Reddy Parine; Jilani Purusottapatnam Shaik; Huda A Alabdulkarim; Sana Abdulla Ajaj; Zahid Khan Journal: PLoS One Date: 2013-03-14 Impact factor: 3.240
Authors: Shiyuan Jing; Lei Chen; Song Han; Ning Liu; MingYang Han; Yakun Yang; Changxiang Yan Journal: Front Neurol Date: 2021-07-08 Impact factor: 4.003